In the current study, our data reported the second-generation MASTL inhibitor MKI-2, a new potent MASTL inhibitor with in vitro IC50 of 37.44 nM and cellular IC50 of 142.7 nM in breast cancer cells. This evidence concerns the gene MASTL and breast cancer.